Evaluation of a measles vaccine campaign by oral-fluid surveys in a rural Kenyan district: interpretation of antibody prevalence data using mixture models by Ohuma, E. O. et al.
  
University of Warwick institutional repository: http://go.warwick.ac.uk/wrap
This paper is made available online in accordance with 
publisher policies. Please scroll down to view the document 
itself. Please refer to the repository record for this item and our 
policy information available from the repository home page for 
further information.  
To see the final version of this paper please visit the publisher’s website. 
Access to the published version may require a subscription. 
 
Author(s): E. O. OHUMA, E. A. OKIRO, A. BETT, J. ABWAO, S. WERE, 
D. SAMUEL, A. VYSE, N. GAY, D. W. G. BROWN and D. J. NOKES
Article Title: Evaluation of a measles vaccine campaign by oral-fluid 
surveys in a rural Kenyan district: interpretation of antibody prevalence 
data using mixture models 
Year of publication: 2008 
Link to published version: 
http://dx.doi.org/10.1017/S0950268808000848 
Publisher statement:  None 
 
 
 
Evaluation of a measles vaccine campaign by oral-ﬂuid surveys
in a rural Kenyan district: interpretation of antibody
prevalence data using mixture models
E. O. OHUMA 1*, E. A. OKIRO1, A. BETT1, J. ABWAO1, S. WERE 2, D. SAMUEL 3,
A. VYSE 4, N. GAY 4, D. W. G. BROWN 3 AND D. J. NOKES1,5
1 Centre for Geographic Medicine Research – Coast, Kenya Medical Research Institute, Kiliﬁ, Kenya
2 Kiliﬁ District Hospital, Kenya
3 Virus Reference Department, Centre for Infections, Health Protection Agency, London, UK
4 Modelling and Economics Unit, Centre for Infections, Health Protection Agency, London, UK
5 Department of Biological Sciences, University of Warwick, Coventry, UK
(Accepted 9 May 2008; ﬁrst published online 10 June 2008)
SUMMARY
We evaluated the eﬀectiveness of a measles vaccine campaign in rural Kenya, based on oral-ﬂuid
surveys and mixture-modelling analysis. Specimens were collected from 886 children aged 9
months to 14 years pre-campaign and from a comparison sample of 598 children aged 6 months
post-campaign. Quantitative measles-speciﬁc antibody data were obtained by commercial kit.
The estimated proportions of measles-speciﬁc antibody negative in children aged 0–4, 5–9 and
10–14 years were 51%, 42% and 27%, respectively, pre- campaign and 18%, 14% and 6%,
respectively, post-campaign. We estimate a reduction in the proportion susceptible of 65–78%,
withy85% of the population recorded to have received vaccine. The proportion of
‘weak’ positive individuals rose from 35% pre-campaign to 54% post-campaign. Our
results conﬁrm the eﬀectiveness of the campaign in reducing susceptibility to measles and
demonstrate the potential of oral-ﬂuid studies to monitor the impact of measles vaccination
campaigns.
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INTRODUCTION
There is now a body of evidence supporting the utility
of minimally invasive oral-ﬂuid collection for immune
status determination [1–7]. Technical diﬃculties in the
sensitivity of assays for antibody detection in oral
ﬂuid have been addressed [1, 8] and oral-ﬂuid anti-
body surveys have shown excellent potential as a
suitable alternative to blood collection especially in
evaluating population immunity prevalence [1, 3, 8].
Wider implementation requires demonstration of a
useful role in vaccine programme development and
reﬁnement, for example, in evaluating the eﬀective-
ness of immunization campaigns. Commercial assays
are now available that aﬀord an easy and standard-
ized approach to anti-measles-speciﬁc IgG antibody
testing in oral-ﬂuid surveys [2, 9]. However, a remain-
ing concern is the performance of oral-ﬂuid antibody
assays in diﬀering settings, for example, populations
with high levels of vaccine-induced immunity with
consequent low-level speciﬁc antibody [2, 10–12].
We undertook an analysis of unpublished data col-
lected at the time of and after a national measles
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vaccination campaign targeting children aged 9
months to 14 years, in a rural district of Kenya in
2002. This campaign formed part of a national ac-
celerated measles control initiative which began in
2002 [13]. The data was analysed using mixture mod-
elling as previously applied successfully to oral-
ﬂuid prevalence data for rubella [1, 8]. The objective
was to assess the use of oral-ﬂuid surveys as a means
of deﬁning population antibody prevalence, assessing
the impact of a mass campaign and estimating the
level of susceptibility in the vaccine recipients. This
is the ﬁrst time mixture modelling has been applied
in the interpretation of oral-ﬂuid data for measles.
METHODS
Sampling
The 2002 campaign evaluation was undertaken in
Kiliﬁ District, coastal Kenya, which comprises a
predominantly rural farming population of around
545 000 [14]. Kiliﬁ town, with around 30000 occu-
pants, is the location of the Kiliﬁ District hospital
(KDH). Oﬃcial statistics (2002) on routine vaccine
uptake for measles in Kiliﬁ District reported a cover-
age of 72% [13]. A measles vaccine campaign was
carried out over the period 17–23 June 2002, following
an operation of public awareness (Ministry of Health,
personal communication). Campaign vaccination sites
included Government health facilities and private
clinics, targeting children aged 9 months to 6 years,
and schools, targeting children aged between 5 and
14 years. The study was undertaken in cooperation
with the local Ministry of Health and Kenyan Ex-
panded Programme on Immunization (KEPI).
Ethical approval for the study was granted by the
Kenya Medical Research Institute (KEMRI)/
National Ethical Review Committee, in Kenya and
Coventry Research Ethics Committee, in the United
Kingdom.
The study sampling design was intended to estimate
antibody prevalence representative of contrasting sec-
tions of the population (rural vs. town), at two time-
points : (i) at the moment of the campaign in order to
assess pre-campaign levels of measles antibody pre-
valence in vaccine recipients (17–23 June 2002), and
(ii)>1 month post-campaign (11 November–20 Dec-
ember 2002), to assess population seroprevalence
inﬂuenced by campaign vaccination. Two locations
from a total of 15 in the district were chosen, namely,
Kiliﬁ township (the town and its immediate surroun-
dings), and Ngerenya, a rural community situated
13 km north of Kiliﬁ town. The pre-campaign survey
consisted of the selection of the main health facility
(Maternal Child Health Clinic at KDH and Ngerenya
Health Centre) and the three largest schools in each
of the two locations. The study proceeded after con-
sultation with the head teacher or senior nurse and
their staﬀ in the schools and clinics respectively and
thereafter study information sheets were provided for
participants. At each health facility, children were
selected on an ad hoc basis up to a maximum of 35
(KDH) or, due to a slower recruitment rate, 25
(Ngerenya), for each age group 9–11, 12–23, 24–35,
36–47, 48–59, and 60–71 months. Within the schools,
samples of 10 children for each yearly age group from
5–14 years were selected as they arrived for vacci-
nation. All participating children were requested to
provide an oral-ﬂuid sample, and data were collected
on previous routine measles vaccination.
For the post-campaign survey, the sampling frame
was the total population of children who, at the time
of the campaign, were aged between 9 months and
14 years within each of the two locations. Children
numbering 100 in each of the age groups: 9 months–4
years, 5–9 years and 10–14 years were selected by
pure random sampling from the register of the demo-
graphic surveillance system (DSS) established by
KEMRI/WellcomeTrustResearch Programme. Local
chiefs were consulted in advance of the study and
information disseminated through meetings of elders.
Field teams visited the family of each child to invite
them to participate in the study, and from those who
consented, an oral-ﬂuid sample was requested, and
data collected on whether the child received measles
vaccine during the campaign. For those whowere aged
<5 years, information on previous routine measles
vaccination uptake was also obtained. Whenever the
participation of a selected child was declined, a re-
placement was selected at random from the census
register. For any child identiﬁed as having not been
vaccinated against measles, the mother was en-
couraged to take the child to the nearest vaccination
centre.
Laboratory methods
Oral-ﬂuid samples were collected by Oracol device
(Malvern Medical Developments, Worcester, UK),
using the method previously described [2, 5]. All speci-
mens were labelled with date of sample collection,
initials of child, and a code comprising sample
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number for speciﬁc age group from speciﬁed school/
clinic. Collected samples were stored in vaccine boxes
with ice packs and transferred at the end of each
working day to the laboratory at KDH. Oral ﬂuids
were processed as previously described and stored
at x80 xC [2, 5], and screened for measles-speciﬁc
antibody using the Microimmune measles IgG EIA
(Microimmune Ltd, Middlesex, UK) according to the
manufacturer’s instructions. This assay was devel-
oped for use with both oral-ﬂuid and serum speci-
mens, and has an antibody capture format which
has been shown to perform well for specimens
with low-level speciﬁc antibody [7, 9]. The antibody
measured in the Microimmune assay is speciﬁc to
the measles nucleoprotein and its detection inter-
preted as an indicator of exposure to virus (via in-
fection or vaccination) rather than a measure of
protection.
Data analysis
The proportion seropositive and seronegative for
measles-speciﬁc IgG antibodies was estimated using
mixture modelling, as previously described for the
analysis of rubella-speciﬁc IgG data from oral-ﬂuid
samples by Gay et al. [1], in order to overcome the
imperfect sensitivity usually associated with oral-ﬂuid
assays. The Microimmune assay data are recorded as
optical density (OD) T/N ratios [test (T), sample OD
reading divided by the average OD readings of three
negative (N), kit controls] for the pre-campaign and
post-campaign. The T/N ratios are log-transformed
to base 10 (log10) for normality and further aggregated
into reactivity categories of equal-width bands on the
log10 scale.
Each individual’s speciﬁc antibody level [log10 (T/
N)] is assumed to fall into one of three status cat-
egories: strong positive, weak positive or negative.
The rationale for including a weak positive group was
to account for possible waning antibody levels with
increasing age, account for lower speciﬁc antibody
levels induced by vaccination compared to those with
wild-type infection and low concentration of speciﬁc
IgG often found in oral ﬂuids at the very limit of de-
tection of the assay systems [12, 15–17].
We further assume that the distribution of the
antibody (reactivity) levels in each status category is
independent of age and follows a normal distribution
and that it is only the proportions in each age group
that vary by status and reactivity category. We ﬁt
three distributions representing each status and
compute the mean and standard deviation of each.
The same model structure and parameters (mean and
standard deviation) are maintained during the pre-
campaign and post-campaign thus enabling the re-
sults of both the pre- and post-campaign to be directly
compared and appropriate conclusions drawn.
We therefore deﬁne a model comprising K=3
components (status categories), where fi(x) denotes
the distribution of reactivity levels (x) for the ith
component and pij denotes the proportion of samples
from the ith component in age group j. Then the
overall density of reactivity levels, at age group j,
Fj(x), is a mixture of the component densities de-
scribed as follows
Fj(x)=
XK
i=1
pijfi(x):
Using 5-year age groups (0–4 years, 5–9 years and
10–14 years), a total of 18 parameters were estimated;
12 describing the proportions negative and weak
positive (with the proportion strong positive deﬁned
as the remainder making unity) in the three age
groups for both pre- and post-campaign and six de-
scribing the mean and standard deviation of the three
statuses. We also analysed the data in single-year
age groups estimating 66 parameters (60 describing
the proportions in each age for both pre- and post-
campaign and six describing the mean and standard
deviation of the three status distributions). Maxi-
mum-likelihood estimates for the model’s param-
eters were estimated by optimization achieved by
minimizing the deviance,D, using the Microsoft Excel
97 Solver Add-In routine (Microsoft Corporation,
USA) where D=2(LLSxLLR), where R is the re-
searcher’s model, S the saturated model, and LL the
log-likelihood. Likelihood-based 95% conﬁdence
intervals (CIs) for the age-speciﬁc prevalence were
obtained by ﬁnding the maximum and minimum
values for which the deviance was within 3.84 (95%
CI of the x2 distribution) of the minimum. Full details
of the method of data preparation, mixture model
derivation, and estimation of parameters with 95%
CIs have been published [1, 8]. The assertion that a
three-distribution mixture model for antibody levels
(i.e. a population of negative, weak positives and
strong positives) provided a better ﬁt to the data than
a two-distribution model (i.e. positives and negatives),
was assessed using the likelihood ratio test, i.e. the
diﬀerence in deviance D for the two models was as-
sessed for signiﬁcance assuming a x2 distribution with
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degrees of freedom equal to the diﬀerence in number
of parameters for the two models.
RESULTS
In the pre-campaign survey 886 children were inter-
viewed, 488 (49% males) from Kiliﬁ town (38% from
KDH, and 20–21% from each of the three schools),
and 398 (47% males) from the rural Ngerenya lo-
cation (23% from the clinic and 25–26% from each
of the three schools). In the post-campaign survey
598 children were interviewed, 294 (52% males) from
Kiliﬁ town and 304 (47% males) from Ngerenya. For
each of the age groups 9 months–4 years, 5–9 years
and 10–14 years, the numbers of children providing
oral-ﬂuid samples pre-vaccination, were 194, 347
and 325. For the corresponding age groups post-
campaign, the numbers sampled were 158, 195 and
201, respectively.
Results from the post-vaccination questionnaire
survey recorded 85% (450/531) of the population as
having received the vaccine during the campaign, with
both locations depicting the same coverage in terms
of the proportion vaccinated. In total, 86% (241/280)
of females were vaccinated compared to 83% (209/
251) of males. The percentage vaccinated was 76%,
93% and 85% in the age groups 0–4, 5–9 and 10–14
years, respectively, and these did not diﬀer signiﬁ-
cantly in the two locations. Veriﬁcation of previous
routine measles vaccination in children aged<5 years
was mostly by parental recall, 93/153 (history, 61%),
compared to 50/153 (33%) conﬁrmed through im-
munization cards. A relatively higher percentage had
card-conﬁrmed routine vaccination in Kiliﬁ township,
31/80 (39%) by card and 44/80 (55%) by parental
recall, compared to the rural location of Ngerenya,
22/85 (26%) and 58/85 (68%), respectively.
A comparison of the frequency distribution of
quantitative data pre- and post-campaign showed a
marked diﬀerence for each of the three age groups
(Fig. 1a–c). The post- vaccination results showed a
more marked skew (‘shift ’) to the right indicating that
this population consists of samples that gave stronger
readings in the assay and therefore contain more
measles-speciﬁc IgG positives. The distribution of re-
activity categories by status (negative, weak positive
and strong positive) are presented in Figure 1d. The
three-distribution (negative, weak positive and strong
positive) mixture model provided a signiﬁcantly im-
proved ﬁt to the data (deviance=129.104 on 108 D.F.)
compared to the two-distribution (negative and
positive) mixture model (deviance=171.996 on 116
D.F., i.e. diﬀerence in deviance 42.892, P value
<0.001).
Overall measles antibody prevalence in the target
age-group of children aged 9 months–14 years was
estimated to be 60% pre-campaign, and 87% post-
campaign. This represents a reduction in susceptibility
prevalence of 70%. Age-speciﬁc reductions in sero-
negative prevalence (shown in Fig. 2) are 65%, 67%,
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Fig. 1. Resultant ﬁt of a mixture model applied to measles-
speciﬁc antibody data from surveys pre- and post-vacci-
nation campaign in Kiliﬁ District, Kenya, 2002. (a–c)
Frequency in percentage by antibody reactivity category
[with equal-width bands based on log OD T/N values – see
main text for explanation)] for pre-campaign raw data (&)
and model ﬁt (——) and post-campaign raw data (#) and
model ﬁt (- - - -) for age groups (a) 0–4 years, (b) 5–9 years,
(c) 10–14 years. (d) The modelled distributions of the posi-
tive, weak positive and negative components.
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and 78% in age groups 9 months–4 years, 5–9 years
and 10–14 years, respectively. However, there remains
a high proportion (11%), antibody negative in 14-
year-olds despite the intense campaign outreach and
vaccination. The prevalence of weak-positive in-
dividuals is 54% post-campaign relative to 35%
pre-campaign, with increases (which are statistically
signiﬁcant) restricted to the 9 months–9 years age
groups (Fig. 2b).
Diﬀerences by location were also noted with 29%
seropositive in Ngerenya (rural) compared to 63%
for Kiliﬁ township pre-vaccination in children aged
<5 years (Fig. 3), but not in older ages. However,
post-campaign, this prevalence diﬀerential between
the two locations in young children was no longer
evident. The proportion of children aged <5 years
who reported routine measles vaccination (by card
or recall) was 83% of 64 children in Ngerenya and
97% of 148 children in Kiliﬁ.
DISCUSSION
A key objective of the present study was to provide
an independent evaluation of the eﬀectiveness of a
measles vaccination campaign undertaken in a typical
predominantly rural developing country setting using
oral-ﬂuid surveys. Estimates of seroprevalence prior
to and after the campaign were obtained by appli-
cation of the method of mixture modelling on speciﬁc
measles antibody data, and based on a similar analy-
sis performed on rubella antibodies derived from oral-
ﬂuid sampling in Ethiopia [1]. It has previously been
shown that a ﬁxed cut-oﬀ method of determining
measles immune status is problematical in popu-
lations with high vaccine coverage, in which speciﬁc
measles antibody levels have been shown to be rela-
tively low, with concomitant problems in assay sensi-
tivity [11, 12]. In this study, we demonstrate the
usefulness of the mixture-modelling approach for
data in which the distributions of antibody levels for
negatives and positives are not easily distinguishable.
This is the ﬁrst example of such an application to
measles serological data.
Our study clearly depicts a considerable impact on
the population measles seropositive prevalence – as-
sumed to reﬂect immunity – resulting from the cam-
paign. We record an overall reduction in seronegative
prevalence ofy70% (range 65–78%). Our question-
naire data suggests around 85% of the population re-
ceived vaccine during the campaign, which is not
inconsistent with the results of a sampling survey of
supplementary immunization activities (SIA) cover-
age for Coast Province in which Kiliﬁ resides [13].
If 85% of susceptible children were vaccinated, and
assuming a vaccine take of 90%, the expected re-
duction in the ‘susceptible ’ proportion is 76.5%
(90%r85%), an estimate consistent with the upper
limit of the estimate from themixturemodel. A smaller
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Fig. 2. Comparison of model estimates of (a) measles sero-
negativity and (b) proportion weakly positive by age group
in children pre-campaign ( ) and post-campaign (%) in
Kiliﬁ District, Kenya, 2002 (95% conﬁdence intervals are
shown).
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Fig. 3. Comparison of model estimates of measles sero-
positivity by age in children aged 1–5 years residing in Kiliﬁ
township ( ) and in a rural area, Ngerenya (%), pre-
campaign, Kiliﬁ District, Kenya, 2002.
Mixture modelling measles-speciﬁc oral-ﬂuid antibody data 231
reduction in susceptibility would be expected if ‘hard
to reach’ children were missed by both routine vacci-
nation and the vaccination campaign [18]. The 70%
reduction shown by our survey data suggests that
the vaccination campaign was largely successful at
reaching previously unvaccinated children. However,
approximately 18% of<5-year-olds still remain sus-
ceptible to measles even after the vaccination cam-
paign hence posing some risk of measles spread.
Furthermore, although the proportion that are sero-
negative decrease as age increases, there is a signiﬁcant
proportion seronegative especially in the 14 years
age group. An additional concern is the low sero-
prevalence of antibody prior to the campaign, sug-
gesting that routine vaccination coverage is low and
that susceptibles will rapidly re-accumulate. It is thus
clear that routine and supplementary immunization
and campaign activities need to be strengthened to
increase population immunity and in order to establish
protective herd immunity.
The optimal study design by which to assess the
eﬀectiveness of the vaccination campaign would have
been a random sample selected from the DSS register
prior to the campaign with follow-up sampling of the
same individuals 1 month after the campaign. As a
pragmatic response to the short notice given for the
campaign we undertook purposive sampling from in-
dividuals attending for vaccination as a substitute for
the pre-campaign randomized survey, and the post-
campaign sample was delayed for 5 months awaiting
oﬃcial clearance. Although the extent of the inﬂuence
of this sampling design on the results is unclear, we
suspect it would not have markedly altered the out-
come since we know from the post-campaign survey
that the vast majority (y85%) of eligible individuals
attended for campaign vaccination (Department of
Health estimates were 90% for the Kenyan coast) and
there was reportedly no instance of measles in the
district in the 6 months post-campaign.
In our study the reduction in the proportion sero-
negative following the vaccine campaign was greater
in the rural location, since the pre-vaccination preva-
lence of measles-speciﬁc antibodies was markedly
lower than in the town location in children aged <5
years. Proportions positive in the rural and town
populations seems to have risen considerably after the
campaign with the rural population rising to relatively
higher levels than the urban population primarily due
to the fact that there were more susceptibles residing
in the rural areas that had not been previously vacci-
nated. The rural population is more at risk compared
to the urban as most of them appear not to seek early
immunization and these diﬀerences could possibly be
attributable to proximity, accessibility (to hospital
and health centres) and lack of information among
the rural population.
The observed increase in high proportions of in-
dividuals with low positive antibody levels (‘weak
positives ’) post-campaign (54%) compared to pre-
campaign (35%) is not unexpected where speciﬁc anti-
bodies are the result of vaccination [17]. Interestingly,
this increase is not identiﬁed in the 10–14 years age
group, suggesting an age-dependence in the antibody
response following vaccination. The role of weakly
positive individuals as a potential source for con-
tinued measles transmission, although unlikely, can-
not be completely discounted. Further studies are
required to establish the relationship between low-
level antibody identiﬁed by mixture-modelling tech-
niques and susceptibility to infection, and relate this
to similar work for ﬁxed cut-oﬀs (see e.g. [12]). This
group of individuals may become signiﬁcant when
very high levels of vaccination arise, resulting in little
wild-type infection, where most immunity is vaccine
induced and correspondingly of low titre, and where
boosting of antibody titres also cannot occur [12, 17].
Data on measles surveillance shows little measles
transmission 4 years post-vaccination, indicative of
an eﬀective campaign with good vaccine eﬃcacy
[13]. However, an epidemic arose in May 2006 to
March 2007 with (196 hospital cases reported, y36/
100 000 in Kiliﬁ District) most of the reported cases
(77%) occurring in early life (<5 years), with 35%
aged <9 months, 18% (9–23 months) and 24%
(24–59 months), compared to 23% occurring in chil-
dren aged >5 years, with 17% (5–9 years) and 6%
(10–12 years). Ironically, a SIA scheduled for July
2005 approximately 36 months after the catch-up
SIA of 2002 [19] was postponed, and implemented in
July 2006. This delay was probably a contributing
factor in bringing about the outbreak, and serves to
emphasize the importance of increasing the levels
of routine measles vaccine uptake and the need for
timely supplementary immunization activities as
suggested by the WHO Regional Oﬃce for Africa
reports [13, 19, 20].
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